New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Acasti Pharma Inc.
ACST
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

34M

Biotechnology

Next Earning date - 19 Jun 2025

34M

Biotechnology

Next Earning date - 19 Jun 2025

3.37USD

Shape0.13 ( 4.01%)
Market Closed (as of Oct 25, 20:00 EDT)
favorite-chart

Relative Strenght

91
favorite-chart

Volume Buzz

-17%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

6%
OverviewChart

Quote Panel

Shape
Updated March 23, 2025
1W % 1M % 3M % 1Y -3.81 %

Key Metrics

Shape

  • Market Cap

    34.17M

  • Shares Outstanding

    10.14M

  • Share in Float

    4.65M

  • Dividende

    0

  • Earning Date

    19 Jun 2025

  • Price Target

    3.37

  • Average Volume

    33247

  • Beta

    1.523

  • Range

    1.98-3.6

  • Industry

    Biotechnology

  • Website

    https://www.acastipharma.com

  • Sector

    Healthcare

Fundamentals

Shape

Relative Strength

Shape

ACST

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape
0

$2.08

Shape-765%

2025-EPS

0

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Shape

Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

No Data Available

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-0.66
vs 0.18

Q4.22

arrow
arrow

N/A

-0.54
vs -0.54

Q1.23

arrow
arrow

N/A

-0.30
vs -0.24

Q2.23

arrow
arrow

N/A

-0.34
vs -0.60

Q3.23

arrow
arrow

N/A

-0.19
vs -0.66

Q4.23

arrow
arrow

N/A

-0.21
vs -0.54

Q1.24

arrow
arrow

N/A

-0.18
vs -0.30

Q2.24

arrow
arrow

N/A

-0.24
vs -0.34

Q3.24

arrow
arrow

N/A

-0.54
vs -0.19

Q4.24

arrow
arrow

N/A

-0.55
vs -0.21

Sales GrowthShape

status-upYoY

Current

Estimates

Q1.22

arrow
arrow

-100%

NA  vs 115K

Q2.22

arrow
arrow

NA

NA  vs NA

Q3.22

arrow
arrow

NA

NA  vs NA

Q4.22

arrow
arrow

NA

NA  vs NA

Q1.23

arrow
arrow

NA

-32000.00  vs NA

Q2.23

arrow
arrow

NA

NA  vs NA

Q3.23

arrow
arrow

NA

NA  vs NA

Q4.23

arrow
arrow

NA

NA  vs NA

Q1.24

arrow
arrow

+100%

NA  vs -32000

Q2.24

arrow
arrow

NA

NA  vs NA

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-5%

-0.05
vs -0.04

Q4.22

arrow
arrow

-4%

-0.04
vs -0.05

Q1.23

arrow
arrow

-43%

-0.43
vs -0.04

Q2.23

arrow
arrow

-6%

-0.06
vs -0.43

Q3.23

arrow
arrow

-6%

-0.06
vs -0.06

Q4.23

arrow
arrow

-4%

-0.04
vs -0.06

Q1.24

arrow
arrow

-5%

-0.05
vs -0.04

Q2.24

arrow
arrow

-4%

-0.04
vs -0.05

Institutionnal OwnershipShape

status-upQoQ

Q1.21

arrow
arrow

20

20
vs 25

-20%

Q2.21

arrow
arrow

20

20
vs 20

NA

Q3.21

arrow
arrow

2

2
vs 20

-90%

Q4.21

arrow
arrow

1

1
vs 2

-50%

Q1.22

arrow
arrow

2

2
vs 1

100%

Q2.22

arrow
arrow

1

1
vs 2

-50%

Q4.22

arrow
arrow

1

1
vs NA

NA

Q1.23

arrow
arrow

1

1
vs 1

NA

Earnings Growth

Latest News

ACST

globenewswire.com

7 hours ago

Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104
ACST

globenewswire.com

8 hours ago

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.
ACST

globenewswire.com

8 hours ago

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update
ACST

globenewswire.com

10 hours ago

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
ACST

zacks.com

10 hours ago

Is Acasti Pharma (ACST) Outperforming Other Medical Stocks This Year?
ACST

globenewswire.com

16 hours ago

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial